A Phase 1b, Single Arm, Multi-center, Open-label, Dose-escalation Study to Assess the Safety and Efficacy of Intravenous BSG005 in Patients with Invasive Fungal Infection
Latest Information Update: 09 Apr 2025
At a glance
- Drugs BSG 005 (Primary)
- Indications Mycoses
- Focus Adverse reactions
- Sponsors Biosergen
Most Recent Events
- 06 Apr 2025 Planned End Date changed from 1 Jun 2025 to 1 Apr 2026.
- 06 Apr 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Dec 2025.
- 13 Nov 2024 New trial record